Drug Profile
SGM 101
Alternative Names: SGM-101Latest Information Update: 19 Apr 2024
Price :
$50
*
At a glance
- Originator SurgiMAb
- Developer Institut du Cancer de Montpellier - Val d'Aurelle; Leiden University Medical Center; SurgiMAb
- Class Antibody diagnostics; Diagnostic conjugates; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Colorectal cancer; Rectal cancer
- Phase II Cancer metastases; Pancreatic cancer
- Preclinical Gastric cancer
- Discontinued Breast cancer; Peritoneal cancer
Most Recent Events
- 19 Apr 2024 Discontinued - Phase-I for Breast cancer (Diagnosis) (IV) before April 2024 (SurgiMab pipeline, April 2024)
- 19 Apr 2024 Discontinued - Phase-I for Peritoneal cancer (Diagnosis) in France (IV) before April 2024 (SurgiMab pipeline, April 2024)
- 19 Apr 2024 Preclinical trials in Gastric cancer in France (IV) before April 2024 (SurgiMab pipeline, April 2024)